Nonsmall Cell Lung Cancer Stage III Clinical Trial
Official title:
Phase II Pilot Study of Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer
This research study aims to determine what effects (good and bad) Durvalumab has on participants and their cancer with a "quick start" of Durvalumab within 14 days of finishing chemotherapy and radiation. The study will also determine the logistic barriers to the quick start of Durvalumab.
Primary Objective: Assess the treatment fidelity for early Durvalumab initiation (i.e., within 14 days after the last day of radiation therapy) following chemoradiation for Stage III, unresectable nonsmall cell lung cancer. Secondary Objectives: - Assess the treatment fidelity for very early Durvalumab initiation (i.e., within seven days after the last day of radiation therapy) following chemoradiation for Stage III, unresectable nonsmall cell lung cancer. - Assess barriers to earlier Durvalumab initiation following chemoradiation for Stage III nonsmall cell lung cancer. - Describe the toxicity of Durvalumab when initiated quickly after chemoradiation for Stage III nonsmall cell lung cancer as compared to historical controls. - Describe the efficacy of Durvalumab when initiated quickly after chemoradiation for Stage III nonsmall cell lung cancer as compared to historical controls. - Describe the patient-reported outcomes of Durvalumab when initiated quickly after chemoradiation for Stage III nonsmall cell lung cancer as compared to historical controls. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT04398199 -
Study of Hypofractionated Radiotherapy Alone in Locally Advanced Nonsmall Cell Lung Cancer Patients
|
Phase 2 | |
| Recruiting |
NCT05873439 -
Genomically Guided Radiation Dose Personalization in Locally Advanced NSCLC
|
Early Phase 1 | |
| Terminated |
NCT01373463 -
Cisplatin and Pemetrexed With Radiation Followed by Lobectomy
|
Phase 1 | |
| Terminated |
NCT04040244 -
Exhaled Breath Analysis to Predict Risk of Symptomatic Pneumonitis
|
N/A | |
| Recruiting |
NCT05692635 -
Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance
|
Phase 2 |